Sweden's BioArtic founded the science behind the Alzheimer's medicine Leqembi - 2026 has been busy with a Parkinson's program and a host of partnerships for it brain transporter technology advancing
CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.